KSHV Cancerogenesis and the Novel Strategies in Vaccine Design
DOI:
https://doi.org/10.54097/hset.v14i.1842Keywords:
KSHV, Cancerogenesis, Cancer Vaccine.Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 (HHV-8) is an oncogenic virus that is associated with Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), multicentric Castleman’s disease (MCD), and other immune disorders. During the millions-year-long co-evolution with human, KSHV has developed a sophisticated system to switch and balance its biphasic latent-lytic lifecycle. To date, tons of efforts have been made to unveil its lifecycle and specific cancerogenesis. However, not a single specific, effective, and widely accessible treatment for this virus has been figured out. This article reviews the basis of the KSHV lifecycle and some important factors to generate malignant cancers and then offers a few novel and feasible vaccination strategies.
Downloads
References
Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma [J]. Science, 1994, 266(5192): 1865-1869.
Aalam F, Totonchy J. Molecular Virology of KSHV in the Lymphocyte Compartment-Insights From Patient Samples and De Novo Infection Models [J]. Front Cell Infect Microbiol, 2020, 10: 607663.
Toth Z, Brulois K, Lee HR, et al. Biphasic euchromatin-to-heterochromatin transition on the KSHV genome following de novo infection [J]. PLoS Pathog, 2013, 9(12): e1003813.
Broussard G and Damania B. Regulation of KSHV Latency and Lytic Reactivation [J]. Viruses, 2020, 12(9): 1034.
Gan J, Wang C, Jin Y, et al. Proteomic profiling identifies the SIM-associated complex of KSHV-encoded LANA [J]. Proteomics, 2015, 15(12): 2023-2037.
Giffin L and Damania B. KSHV: pathways to tumorigenesis and persistent infection [J]. Adv Virus Res, 2014, 88: 111-159.
Mariggiò G, Koch S, Schulz TF. Kaposi sarcoma herpesvirus pathogenesis [J]. Philos Trans R Soc Lond B Biol Sci, 2017, 372(1732): 20160275.
Tornesello AL, Tagliamonte M, Buonaguro FM, et al. Virus-like Particles as Preventive and Therapeutic Cancer Vaccines [J]. Vaccines (Basel), 2022, 10(2): 227.
Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy [J]. Mol Cancer, 2021, 20(1): 41.
Robey RC, Mletzko S, Gotch FM. The T-Cell Immune Response against Kaposi's Sarcoma-Associated Herpesvirus [J]. Adv Virol, 2010, 2010: 340356.
Lepone L, Rappocciolo G, Knowlton E, et al. Monofunctional and polyfunctional CD8+ T cell responses to human herpesvirus 8 lytic and latency proteins [J]. Clin Vaccine Immunol, 2010, 17(10): 1507-1516
Wu TT, Qian J, Ang J, Sun R. Vaccine prospect of Kaposi sarcoma-associated herpesvirus [J]. Curr Opin Virol, 2012, 2(4): 482-488.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
